» Articles » PMID: 25613107

Characterisation of the Frequent Exacerbator Phenotype in COPD Patients in a Large UK Primary Care Population

Overview
Journal Respir Med
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2015 Jan 24
PMID 25613107
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The 'frequent exacerbator' is recognised as an important phenotype in COPD. Current understanding about this phenotype comes from prospective longitudinal clinical trials in secondary/tertiary care with little information reported in primary care populations.

Aims: To characterize the frequent-exacerbator phenotype and identify associated risk factors in a large UK primary care COPD population.

Methods: Using a large database of primary care patients from 80 UK general practices, patients were categorised using GOLD 2014 criteria into high and low risk groups based on exacerbation history. A multivariate logistic regression model was used to investigate covariates associated with the frequent-exacerbator phenotype and risk of experiencing a severe exacerbation (leading to hospitalisation).

Results: Of the total study population (n = 9219), 2612 (28%) fulfilled the criteria for high risk frequent-exacerbators. Independent risk factors (adjusted odds ratio [95% CI]) for ≥2 exacerbations were: most severely impaired modified Medical Research Council (mMRC) dyspnoea score (mMRC grade 4: 4.37 [2.64-7.23]), lower FEV1 percent predicted (FEV1 <30%: 2.42 [1.61-3.65]), co-morbid cardiovascular disease (1.42 [1.19-1.68]), depression (1.56 [1.22-1.99]) or osteoporosis (1.54 [1.19-2.01]), and female gender (1.20 [1.01-1.43]). Older patients (≥75 years), those with most severe lung impairment (FEV1 <30%), those with highest mMRC score and those with co-morbid osteoporosis were identified as most at risk of experiencing exacerbations requiring hospitalisation.

Conclusions: Although COPD exacerbations occur across all grades of disease severity, female patients with high dyspnoea scores, more severely impaired lung function and co-morbidities are at greatest risk. Elderly patients, with severely impaired lung function, high mMRC scores and osteoporosis are associated with experience of severe exacerbations requiring hospitalisation.

Citing Articles

Change in exacerbation rate of COPD patients before and after COVID-19 infection.

Choi J, Kim K, Rhee C Sci Rep. 2025; 15(1):2427.

PMID: 39827278 PMC: 11743209. DOI: 10.1038/s41598-025-86426-9.


Sex-differences in COPD: from biological mechanisms to therapeutic considerations.

Milne K, Mitchell R, Ferguson O, Hind A, Guenette J Front Med (Lausanne). 2024; 11:1289259.

PMID: 38572156 PMC: 10989064. DOI: 10.3389/fmed.2024.1289259.


Inhaled systemic corticosteroids for acute exacerbations of COPD: a systematic review and meta-analysis.

Papadopoulou E, Bin Safar S, Khalil A, Hansel J, Wang R, Corlateanu A Eur Respir Rev. 2024; 33(171).

PMID: 38508668 PMC: 10951861. DOI: 10.1183/16000617.0151-2023.


Prevalence of Cardiovascular Disease and Rate of Major Adverse Cardiovascular Events in Severe Alpha-1 Antitrypsin Deficiency COPD.

Ellis P, Bailey E, Choate R, Holm K, Sandhaus R, Turner A Int J Chron Obstruct Pulmon Dis. 2024; 19:149-159.

PMID: 38249829 PMC: 10800105. DOI: 10.2147/COPD.S419846.


Effect of Broncho-Vaxom (OM-85) on the frequency of chronic obstructive pulmonary disease (COPD) exacerbations.

Choi J, Park Y, An T, Yoo K, Rhee C BMC Pulm Med. 2023; 23(1):378.

PMID: 37805515 PMC: 10559651. DOI: 10.1186/s12890-023-02665-4.